27 October 2026
Latham Advises on Corxel Pharmaceuticals and Amanat Acquisition Corp.’s Business Combination Agreement to Create a Publicly Listed Obesity-Focused Biopharmaceutical Company
Advising firms
Deal team
6 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nathan Ajiashvili Lead | Latham & Watkins LLP | Partner | corporate | New York |
| Alison Haggerty Lead | Latham & Watkins LLP | Partner | corporate | New York |
| Sandy Kugbei Lead | Latham & Watkins LLP | Partner | corporate | New York |
| Adam Weber | Latham & Watkins LLP | Associate | corporate | Not stated |
| Don Izekor | Latham & Watkins LLP | Associate | corporate | Not stated |
| Sam Berry | Latham & Watkins LLP | Associate | corporate | Not stated |
3 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- Not stated
- Counterparties
- Corxel Pharmaceuticals, Inc. (Target)
Amanat Acquisition Corp. (Buy-side)